Direct-acting antiviral therapy reduces variceal rebleeding and improves liver function in hepatitis C virus-related cirrhosis: A multicenter retrospective cohort study

Table 1 Baseline characteristics of the studied groups

Variables	Group A (DAA-Treated)	Group B (Non-DAA-Treated)	P value
Demographics
Age (years)	48.7 ± 4.2	47.4 ± 4.6	0.137
BMI (kg/m2)	22.7 ± 1.6	23.2 ± 1.3	0.121
Comorbidities, n (%)
Hypertension	18 (31)	16 (27)	0.839
Dyslipidemia	11 (19)	15 (25)	0.506
Laboratory data
Hemoglobin (g/dL)	13.7 ± 1.5	14 ± 1.8	0.336
Platelets (10³/μL)	156.1 ± 39.6	166.4 ± 37.5	0.149
Creatinine (mg/dL)	0.9 ± 0.3	1 ± 0.3	0.095
Albumin (g/dL)	3.4 ± 0.4	3.6 ± 0.9	0.062
INR	1.5 ± 0.8	1.6 ± 0.9	0.671
ALT (U/L)	45 ± 15	50 ± 18	0.210
AST (U/L)	50 ± 20	55 ± 22	0.180
Bilirubin (mg/dL)	1.5 ± 0.8	1.6 ± 0.9	0.671
Alkaline phosphatase (U/L)	120 ± 30	130 ± 35	0.150
Liver Stiffness (FibroScan)
LSM (kPa)	15.2 ± 2.1	15.5 ± 2.3	0.450
Clinical features, n (%)
Ascites	4 (6.8)	16 (27.1)	0.006
MELD score	9 (8-10)	9 (7-10)	0.206
Child-Pugh Class, n (%)
Child-Pugh class A	56 (94.9)	38 (64.4)	< 0.001
Child-Pugh class B	3 (5.1)	21 (35.6)	< 0.001

Data presented as mean ± SD, median (Q1-Q3).

BMI: Body mass index; INR: International normalized ratio; LSM: Liver stiffness measures; MELD: Model for end-stage liver disease; DAA: Direct-acting antiviral; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.